Foodborne botulism outbreak with potential new management options

References

1. 1.↵
   1. Rao AK,
   2. Sobel J,
   3. Chatham-Stephens K,
   4. Luquez C

   . Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR Recomm Rep 2021; 70: 1–30.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Humeau Y,
   2. Doussau F,
   3. Grant NJ,
   4. Poulain B

   . How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000; 82: 427–446.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Sobel J

   . Botulism. Clin Infect Dis 2005; 41: 1167–1173.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Yu PA,
   2. Lin NH,
   3. Mahon BE,
   4. Sobel J,
   5. Yu Y,
   6. Mody RK, et al.

   Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis 2017; 66: S57–S64.

   OpenUrl
5. 5.↵
   1. Fleck-Derderian S,
   2. Shankar M,
   3. Rao AK,
   4. Chatham-Stephens K,
   5. Adjei S,
   6. Sobel J, et al.

   The epidemiology of foodborne botulism outbreaks: a systematic review. Clin Infect Dis 2017; 66: S73–S81.

   OpenUrl
6. 6.↵
   1. Zhang N,
   2. Hong D,
   3. Ouyang T,
   4. Meng W,
   5. Huang J,
   6. Li M, et al.

   3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials. BMC Neurol 2021; 21: 371.

   OpenUrl
7. 7.↵
   1. Sanders DB

   . 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann N Y Acad Sci 1998; 841: 811–816.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Lundh H,
   2. Nilsson O,
   3. Rosén I

   . Novel drug of choice in Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 1983; 46: 684–685.

   OpenUrlFREE Full Text
9. 9.
   1. Lundh H,
   2. Nilsson O,
   3. Rosén I

   . Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984; 34: 1324–1330.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. McEvoy KM,
    2. Windebank AJ,
    3. Daube JR,
    4. Low PA

    . 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321: 1567–1571.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Sanders DB,
    2. Massey JM,
    3. Sanders LL,
    4. Edwards LJ

    . A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000; 54: 603–607.

    OpenUrl
12. 12.↵
    1. Wirtz PW,
    2. Verschuuren JJ,
    3. van Dijk JG,
    4. de Kam ML,
    5. Schoemaker RC,
    6. van Hasselt JG, et al.

    Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009; 86: 44–48.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Wirtz PW,
    2. Titulaer MJ,
    3. Gerven JM,
    4. Verschuuren JJ

    . 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol 2010; 6: 867–874.

    OpenUrlPubMed